Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

Medicina (Kaunas). 2019 Jul 3;55(7):336. doi: 10.3390/medicina55070336.

Abstract

A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy. Six months after BT, a diagnosis of severe asthma with eosinophilic chronic rhinosinusitis (ECRS) was made and benralizumab treatment was initiated; the blood eosinophil count subsequently decreased and lung function improved, thereby permitting OCS dose tapering. Surprisingly, benralizumab both reduced nasal polyps and ameliorated ECRS. Thus, benralizumab may be a useful drug for the rapid treatment of severe asthma with ECRS, especially in patients with hypereosinophilia.

Keywords: benralizumab; bronchial thermoplasty; eosinophilic chronic rhinosinusitis; hypereosinophilia; severe asthma.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / complications
  • Asthma / drug therapy*
  • Bronchial Thermoplasty / methods
  • Disease Progression
  • Eosinophilia / complications
  • Eosinophilia / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Sinusitis / complications
  • Sinusitis / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • benralizumab